The estimated Net Worth of Erik Danielsen is at least $2.19 Milhão dollars as of 21 December 2018. Mr. Danielsen owns over 6,000 units of Nymox Pharmaceutical Corp stock worth over $4,180 and over the last 6 years he sold NYMX stock worth over $0. In addition, he makes $2,187,940 as Chief Financial Officer at Nymox Pharmaceutical Corp.
Sign up
Mr. Danielsen NYMX stock SEC Form 4 insiders trading
Erik has made over 2 trades of the Nymox Pharmaceutical Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of NYMX stock worth $8,100 on 21 December 2018.
The largest trade he's ever made was buying 6,000 units of Nymox Pharmaceutical Corp stock on 21 December 2018 worth over $8,100. On average, Erik trades about 5,500 units every 1 days since 2018. As of 21 December 2018 he still owns at least 20,900 units of Nymox Pharmaceutical Corp stock.
You can see the complete history of Mr. Danielsen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Erik Danielsen biography
Erik Danielsen serves as Chief Financial Officer of the Company. Mr. Danielsen is a graduate from University de Fribourg with a Master’s in Business Law and Corporate Finance. Mr. Danielsen a former Senior Auditor for Price Waterhouse and has extensive experience in international business. Mr. Danielsen is a former Credit Suisse Equity Strategist.
What is the salary of Erik Danielsen?
As the Chief Financial Officer of Nymox Pharmaceutical Corp, the total compensation of Erik Danielsen at Nymox Pharmaceutical Corp is $2,187,940. There are 1 executives at Nymox Pharmaceutical Corp getting paid more, with Paul Averback having the highest compensation of $2,318,000.
How old is Erik Danielsen?
Erik Danielsen is 57, he's been the Chief Financial Officer of Nymox Pharmaceutical Corp since 2015. There are 6 older and 1 younger executives at Nymox Pharmaceutical Corp. The oldest executive at Nymox Pharmaceutical Corp is James Robinson, 84, who is the Independent Director.
What's Erik Danielsen's mailing address?
Erik's mailing address filed with the SEC is 9900 Boul Cavendish, Saint-Laurent, QC H4M 2V2, Canada.
Insiders trading at Nymox Pharmaceutical Corp
Over the last 9 years, insiders at Nymox Pharmaceutical Corp have traded over $4,394,000 worth of Nymox Pharmaceutical Corp stock and bought 2,534,915 units worth $5,846,809 . The most active insiders traders include James George Robinson, Paul Averback, eErik Danielsen. On average, Nymox Pharmaceutical Corp executives and independent directors trade stock every 27 days with the average trade being worth of $9,606. The most recent stock trade was executed by James George Robinson on 2 May 2022, trading 1,151,515 units of NYMX stock currently worth $1,900,000.
What does Nymox Pharmaceutical Corp do?
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
What does Nymox Pharmaceutical Corp's logo look like?
Complete history of Mr. Danielsen stock trades at Nymox Pharmaceutical Corp
Nymox Pharmaceutical Corp executives and stock owners
Nymox Pharmaceutical Corp executives and other stock owners filed with the SEC include:
-
Paul Averback,
Chairman of the Board, President, Chief Executive Officer -
Erik Danielsen,
Chief Financial Officer -
Erik Danielsen,
CFO & Controller -
Randall Lanham,
General Counsel, Director -
Randall J. Lanham Esq., J.D.,
Gen. Counsel, Sec., COO & Director -
James Robinson,
Independent Director -
David Morse,
Independent Director -
Richard Cutler,
Independent Director -
Lin Dodd,
QA and Compliance Mang. -
Dr. Paul Averback DABP, M.D.,
Founder, Chairman, CEO & Pres